A Study Using the CIVO Platform to Evaluate Intratumoral Microdoses of Anti-Cancer Therapies in Patients with Solid Tumors
Enrolling By Invitation
18-99 years
All
Phase
1
10 participants needed
1 Location
Brief description of study
A study designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients with surface accessible solid tumors for which there is a scheduled surgical intervention.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Solid Tumors
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Pathologic diagnosis of solid tumors
Updated on
01 Aug 2024.
Study ID: 844966
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
